Venlafaxine Tablet, Extended Release
Product Images NDC 52427-632

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine (NDC 52427-632). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Almatica Pharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A dot plot chart illustrating the fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax, AUC) of venlafaxine and its metabolite ODV across various special populations including hepatic (cirrhosis, mild, moderate impairment), renal (mild/moderate impairment, hemodialysis), CYP2D6 polymorphism, age over 60 years, and gender. The x-axis shows change relative to the reference value, and the right column provides dosing recommendations.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A pharmacokinetic (PK) fold change chart showing the effects of various interacting drugs on venlafaxine and its metabolite ODV. The chart displays changes in Cmax and AUC relative to a reference value, with recommendations on concomitant use or dose adjustment for each interacting drug, including ethanol, diazepam, cimetidine, ketoconazole (in CYP2D6 EM's and PM's), indinavir, metoprolol, imipramine, and lithium.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A chart depicting the pharmacokinetic fold change and 90% confidence intervals for various analytes when co-administered with venlafaxine extended-release tablets. It includes interacting drugs (e.g., diazepam, alprazolam, metoprolol) and their analytes, showing changes in Cmax and AUC relative to reference values. Recommendations such as 'No dose adjustment' or 'Use with caution, monitor blood pressure' are noted.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure diagram depicting venlafaxine as the active ingredient, including a methoxy-substituted phenyl ring, a cyclohexanol group, and a dimethylaminoethyl side chain, with a benzenesulfonate and water molecule indicated as part of the structure.*
FDA Label Image

Label (Venlafaxine Label)

Label (Venlafaxine Label)
Label for Venlafaxine Extended-Release Tablets 112.5 mg by Almatica Pharma LLC. The label shows active ingredient strength as 112.5 mg per tablet in extended-release oral tablet form. The package contains 30 tablets. Manufacturing and distribution information includes Norwich Pharmaceuticals, Inc. and Almatica Pharma LLC. Storage instructions specify controlled room temperature.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.